Modeling recombinant immunotoxin efficacies in solid tumors

Annals of Biomedical Engineering

Volumn 36, Issue 3, 2008, Pages 486-512

  Chen, Kevin C ^a   Kim, Junho ^a   Li, Xinmei ^a,b   Lee, Byungkook ^c  

^a FLORIDA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS AT DALLAS   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Binding site barriers; Modeling; Recombinant immunotoxin; Simulations; Solid tumor

Indexed keywords

BINDING SITES; COMPUTER SIMULATION; MATHEMATICAL MODELS; ONCOLOGY; PROTEINS;

CANCER THERAPY; RECOMBINANT IMMUNOTOXINS (RIT); SOLID TUMOR;

TUMORS;

ANTINEOPLASTIC AGENT; IMMUNOTOXIN; RECOMBINANT PROTEIN;

ARTICLE; BIOLOGICAL MODEL; CELL PROLIFERATION; CELL SURVIVAL; COMPUTER ASSISTED DRUG THERAPY; COMPUTER SIMULATION; DRUG EFFECT; HUMAN; METHODOLOGY; NEOPLASM; PATHOLOGY; PATHOPHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COMPUTER SIMULATION; DRUG THERAPY, COMPUTER-ASSISTED; HUMANS; IMMUNOTOXINS; MODELS, BIOLOGICAL; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 39149129980     PISSN: 00906964     EISSN: 15739686     Source Type: Journal    
DOI: 10.1007/s10439-007-9425-4     Document Type: Article

References (59)

1. Adams G. P., Schier R., McCall A. M., Simmons H. H., Horak E. M., Alpaugh R. K., Marks J. D., Weiner L. M. (2001) High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res 61:4750-4755
2. Bang S., Nagata S., Onda M., Kreitman R. J., Pastan I. (2005) HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity. Clin. Cancer Res. 11:1545-1550
3. Benhar I., Pastan I. (1995) Identification of residues that stabilize the single-chain Fv of monoclonal antibodies B3. J. Biol. Chem. 270:23373-23380
4. Bera T. K., Onda M., Brinkmann U., Pastan I. (1998) A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2. J. Mol. Biol. 281:475-483
5. Bera T. K., Viner J., Brinkmann E., Pastan I. (1999) Pharmacokinetics and antitumor activity of a bivalent disulfide-stabilized Fv immunotoxin with improved antigen binding to erbB2. Cancer Res. 59:4018-4022
6. Bera T. K., Williams-Gould J., Beers R., Chowdhury P., Pastan I. (2001) Bivalent disulfide-stabilized fragment variable immunotoxin directed against mesotheliomas and ovarian cancer. Mol. Cancer Ther. 1:79-84
7. Bigner D. D., Archer G. E., McLendon R. E., Friedman H. S., Fuchs H. E., Pai L. H., Herndon J. E., Pastan I. (1995) Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis. Clin. Cancer Res. 1:1545-1555
8. Breward C. J. W., Byrne H. M., Lewis C. E. (2001) Modeling the interactions between tumor cells and a blood vessel in a microenvironment within a vascular tumor. Eur. J. Appl. Math. 12:529-556
9. Brinkmann U., Pai L. H., FitzGerald D. J., Willingham M., Pastan I. (1991) B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. Proc. Natl. Acad. Sci. USA 88:8616-8620
10. Brinkmann U., Pastan I. (1995) Recombinant immunotoxins: from basic research to cancer therapy. Methods 8:143-156
11. Bruehlmeier M., Roelcke U., Blauenstein P., Missimer J., Schubiger P. A., Locher J. T., Pellikka R., Ametamey S. M. (2003) Measurement of the extracellular space in brain tumors using 76Br-bromide and PET. J. Nucl. Med. 44:1210-1218
12. Chan C. H. T., Wang J., French R. R., Glennie M. J. (1998) Internalization of the lymphocytic surface protein CD22 is controlled by a novel membrane proximal cytoplasmic motif. J. Biol. Chem. 273: 27809-27815
13. Chang M. P., Bramhall J., Graves S., Bonavida B., Wisnieski B. J. (1989) Internucleosomal DNA cleavage proceeds diphtheria toxin-induced cytolysis: evidence that cell lysis is not a simple consequence of translation inhibition. J. Biol. Chem. 264:15261-15267
14. Chang K., Pai L. H., Bera J. K., Pastan I., Willingham M. C. (1992) Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium. Cancer Res. 52:181-186
15. Chowdhury P. S., Pastan I. (1999) Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat. Biotechnol. 17:568-572
16. Chowdhury P. S., Viner J. L., Beers R., Pastan I. (1998) Isolation of a high-affinity stable single chain Fv specific for mesothelin from DNA-immunized mice by phage display and construction of a recombinant immunotoxin with anti-tumor activity. Proc. Natl. Acad. Sci. USA 95:669-674
17. EGFR -RTA in ovarian cancer cells. Clin. Cancer Res. 4:2545-2550
18. Filho I. P. T., Leunig M., Yuan F., Intaglietta M., Jain R. K. (1994) Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice. Proc. Natl. Acad. Sci. USA 91:2081-2085
19. Graff C. P., Wittrup K. D. (2003) Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 63:1288-1296
20. 111Indium-labeled monoclonal antibody K1: biodisitribution study in nude mice bearing a human carcinoma xenograft expressing mesothelin. Int. J. Cancer 80:559-563
21. Hessler J. L., Kreitman R. J. (1997) An early step in Pseudomonas exotoxin action is removal of the terminal lysine residue, which allows binding to the KDEL receptor. Biochemistry 36:14577-14582
22. Hudson T. H., Neville D. M. Jr (1987) Temporal separation of protein toxin translocation from processing events. J. Biol. Chem. 262:16484-16494
23. Jackson T. L. (2002) Vascular tumor growth and treatment: consequences of polyclonality, competition and dynamic vascular support. J. Math. Biol. 44:201-226
24. Jackson T. L. (2003) Intracellular accumulation and mechanism of action of doxorubicin in a spatio-temporal tumor model. J. Theor. Biol. 220:201-213
25. Jain R. K. (2001) Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 46:149-168
26. Juweid M., Neumann R., Paik C., Perez-Bacete M. J., Sato J., Van Osdol W., Weinstein J. N. (1992) Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res. 52:5144-5153
27. Kirpotin D., Park J. W., Hong K., Zalipsky S., Li W.-L., Carter P., Benz C. C., Papahadjopoulos D. (1997) Sterically stabilized anti-Her2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry 36:66-75
28. 125I-labeled anti-Tac single-chain Fv recombinant immunotoxin. J. Nucl. Med. 41:755-762
29. Kochi S. K., Collier R. J. (1993) DNA fragmentation and cytolysis in U937 cells treated with diphtheria toxin or other inhibitors of protein synthesis. Exp. Cell Res. 208:296-302
30. Kreitman R. J., Bailon P., Chaudahry V. K., FitzGerald D. J., Pastan I. (1994) Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expression human carcinoma. Blood 83:426-434
31. Kreitman R. J., Margulies I., Stetler-Stevenson M., Wang Q.-C., FitzGerald D. J. P., Pastan I. (2000) Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias. Clin. Cancer Res. 6:1476-1487
32. Kreitman R. J., Pastan I. (1998) Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res. 58:968-975
33. Kreitman R. J., Wang Q.-C., FitzGerald D. J., Pastan I. (1999) Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys. Int. J. Cancer 81:148-155
34. Krupp M. N., Connolly D. T., Lane M. D. (1982) Synthesis, turnover, and down-regulation of epidermal growth factor receptors in human A431 epidermoid carcinoma cells and skin fibroblasts. J. Biol. Chem. 257:11489-11496
35. Mansfield E., Amlot P., Pastan I., FitzGerald D. J. (1997) Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors. Blood 90:2020-2026
36. Moynihan M. R., Pappenheimer A. M. (1981) Kinetics of adenosinediphosphoribosylation of elongation factor 2 in cells exposed to diphtheria toxin. Infect. Immun. 32:575-582
37. Olsnes S., Sandvig K., Refsnes K., Pihl A. (1976) Rates of different steps involved in the inhibition of protein synthesis by the toxic lectins brin and ricin. J. Biol. Chem. 257:3985-3992
38. Onda M., Kreitman R. J., Vasmatzis G., Lee B., Pastan I. (1999) Reduction of the nonspecific animal toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point. J. Immunol. 163:6072-6077
39. Onda M., Nagata S., Tsutsumi Y., Vincent J. J., Wang Q.-C., Kreitman R. J., Lee B., Pastan I. (2001) Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting anti-tumor activity. Cancer Res. 61:5070-5077
40. Pai L. H., Janendra K. B., FitzGerald D. J., Willingham M. C., Pastan I. (1991) Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin. Proc. Natl. Acad. Sci. USA 88:3358-3362
41. Press W. H., Teukolsky S. A., Vetterling W. T., Flannery B. P. (1996) Numerical Recipes in Fortran 90. 2nd Edition. Cambridge University Press, New York
42. Reiter Y., Brinkmann U., Jung S.-H., Lee B., Kasprzyk P. G., King C. R., Pastan I. (1994) Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. J. Biol. Chem. 269:18327-18331
43. Reiter Y., Brinkmann U., Kreitman R. J., Jung S.-H., Lee B. K., Pastan I. (1994) Stabilization of the Fv fragments in recombinant immunotoxins by disulfide bonds engineered into conserved framework regions. Biochem. 33:5451-5459
44. Reiter Y., Kreitman R. J., Brinkmann U., Pastan I. (1994) Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin. Int. J. Cancer 58:142-149
45. Reiter Y., Pai L. H., Brinkmann U., Wang Q.-C., Pastan I. (1994) Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Cancer Res. 54:2714-2718
46. Reiter Y., Pastan I. (1998) Recombinant Fv immunotoxins and Fv fragments as novel agents for cancer therapy and diagnosis. Trends Biotechnol. 16:513-520
47. Rippley R. K., Stokes C. L. (1995) Effects of cellular pharmacology on drug distribution in tissues. Biophys. J. 69:825-839
48. Rönnberg B. J., Middlebrook J. L. (1989) Cellular regulation of diphtheria toxin cell surface receptors. Toxicon 27:1377-1388
49. Salvatore G., Beers R., Margulies I., Kreitman R. J., Pastan I. (2002) Improved cytotoxicity activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display. Clin. Cancer Res. 8:995-1002
50. Skretting G., Torgersen M. L., Van Deurs B., Sandvig K. (1999) Endocytosis mechanisms responsible for GPI-linked diphtheria toxin receptor. J. Cell Sci. 112:3899-3909
51. Sung C., Shockley T. R., Morrison P. F., Dvorak H. F., Yarmush M. L., Dedrick R. L. (1992) Predicted and observed effects of antibody and antigen density on monoclonal antibody uptake in solid tumors. Cancer Res. 52:377-384
52. Tsutsumi Y., Onda M., Nagata S., Lee B., Kreitman R. J., Pastan I. (2000) Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc. Natl. Acad. Sci. USA 97:8548-8553
53. Uchida T., Pappenheimer A. M., Harper A. A. (1973) Diphtheria toxin and related proteins. II. Kinetic studies on intoxication of Hela cells by diphtheria toxin and related proteins. J. Biol. Chem. 248:3845-3850
54. Van Horssen P. J., Van Oosterhout Y. V., De Witte T., Preijers F. W. (1995) Cytotoxic potency of CD22-ricin A depends on intracellular routing rather than on the number of internalized molecules. Scand. J. Immunol. 41:563-569
55. Vargova L., Homola A., Zamecnik J., Tichy M., Benes V., Sykova E. (2003) Diffusion parameters of the extracellular space in human gliomas. Glia 42:77-88
56. Vincensini D., Dedieu V., Eliat P. A., Vincent C., Bailly C., de Certaines J., Joffre F. (2007) Magnetic resonance imaging measurements of vascular permeability and extracellular volume fraction of breast tumors by dynamic Gd-DTPA-enhanced relaxometry. Magn. Reson. Imaging 25: 293-302
57. Weinstein J. N., VanOsdol W. (1992) Early intervention in cancer using monoclonal antibodies and other biological ligands: micropharmacology and the "binding site barrier". Cancer Res. 52:2747s-2751s
58. Wenning L. A., Murphy R. M. (1999) Coupled cellular trafficking and diffusional limitations in delivery of immunotoxins to multicell tumor spheroids. Biotechnol. Bioeng. 62:562-575
59. Yuan F., Leunig M., Berk D. A., Jain R. K. (1993) Microvascular permeability of albumin, vascular surface area, and vascular volume measured in human adenocarcinoma LS174T using dorsal chamber in SCID mice. Microvasc. Res. 45:269-289